Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib Combined With Sintilimab as First-line Treatment for Advanced Non-liver Metastatic Colorectal Cancer
NCT07398326Phase 2Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib, sintilimab in colorectal cancer (CRC), sponsored by Shanghai Changzheng Hospital. Started Feb 2026; status: recruiting.
02
Drugs
anlotinibsintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07398326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07398326.